Mobile-Directly Observed Therapy on Adherence to Hydroxyurea

Muhimbili University of Health and Allied Sciences98 enrolled

Overview

To examine the effect of mobile-directly observed therapy (mDOT) on adherence to HU (mDOT-HuA) adults with SCA at Muhimbili National Hospital (MNH) in Tanzania.

Background: Hydroxyurea (HU) has been demonstrated to be efficacious in reducing complications in individuals with Sickle Cell Anemia (SCA) but poor adherence is a barrier to improving outcomes in patients with SCA. Directly Observed Therapy (DOT) has been shown to improve adherence in various chronic diseases but there is limited data in adults with sickle cell anaemia (SCA). Methods and design: To examine the effect of mobile-directly observed therapy (mDOT) on adherence to HU (mDOT-HuA) adults with SCA at Muhimbili National Hospital (MNH) in Tanzania.The mDOT-HuA study is single centre, prospective, randomized, open label clinical trial. 100 participants with SCA with hemoglobin SS genotype, aged ≥18 years, living in urban Dar es Salaam and able and willing to participate in the study. Participants will be divided into two treatment arms; 50 in standard monitoring (SM) arm: will receive fixed dose HU therapy with standard monitoring. 50 in treatment mDOT arm: will receive fixed dose HU therapy with standard monitoring and a mobile direct observed web based medication adherence monitoring system. The primary outcome is adherence to HU as defined as medication possession ratio of ≥80 at end of 3 months of HU treatment and mDOT monitoring. Secondary outcomes will be efficacy to HU treatment as measured through the the mean change in fetal hemoglobin (between baseline and end of 3 months) and safety, measured as the proportion of participants experiencing serious adverse events related to HU at week 2, 6, 10 and at the end of 3 months. REDCap, an open source software application will be used to collect data using clinical research forms. Conclusion: This project has the potential for the development of novel strategies for improving HU adherence in SCA.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Sickle Cell Anaemia

Interventions

HydroxyureaDRUG

Patients will receive fixed dose Hydroxyurea therapy (15 mg/Kg/day) with standard monitoring

Mobile Directly Observed TherapyDEVICE

Mobile DOT will consist of a web based medication adherence monitoring system that includes direct video confirmation of adherence using the patient's personal cellular telephone. Patients will receive alerts on their cell phone at pre-arranged times to remind them to take their medications.

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Age ≥18 years and living in urban Dar es Salaam * Male or female (post-menopausal, sterile, or using an acceptable method of contraception) * Negative urine pregnancy test at Screening and a negative urine pregnancy test (dipstick) prior to randomization and dosing * Hemoglobin SS genotype * Absolute neutrophil count \>1,500/uL * Platelet count \>95,000/uL * Serum creatinine\< 100 µmol/L (1.2 mg/dL) * Alanine transaminase (ALT) less than two times the upper limit of normal * Being able and willing to record and submit videos electronically Exclusion Criteria: * Chronic transfusion program as defined by participating in a scheduled (pre-planned) series of transfusions for prophylactic purposes or has a hemoglobin A level that is \>20% of the total hemoglobin * Hemoglobin \<4.0 g/dL * HIV positive * Female planning to become pregnant during the study period * Serious mental (including psychosis) or physical illness, which, in the opinion of the Investigators would compromise participation in the study (e.g. impaired mental capacity, alcoholism * Any condition which the Investigators judge to preclude safe participation in the study or to confound the evaluation of the study outcome.

Locations (1)

Muhimbili University of Health and Allied Sciences

Dar es Salaam, Tanzania

Outcomes

Primary Outcomes

The proportion of participants achieving ≥80% HU adherence as assessed through medication possession ratio.

The proportion of participants achieving ≥80% HU adherence will compared between the two arms.

Time frame: At the end of 3 months of Hydroxyurea treatment and monitoring.

Secondary Outcomes

Efficacy of Hydroxyurea treatment as measured through the mean change in fetal hemoglobin (%),

The mean change in fetal hemoglobin (between baseline and end of 3 months) will be compared between the two arms.

Time frame: At the end of 3 months of Hydroxyurea treatment and monitoring.

The proportion of participants experiencing serious adverse events (SAE) related to hydroxyurea

The overall proportion of participants experiencing SAE during the 3 months of Hydroxyurea treatment will be evaluated as a measure of the safety of treatment with Hydroxyurea

Time frame: at week 2, 6 ,10 and at the end of 3 months of Hydroxyurea treatment and monitoring.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.